GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » PositiveID Corp (OTCPK:PSID) » Definitions » Cash Flow from Financing

PositiveID (PositiveID) Cash Flow from Financing : $2.02 Mil (TTM As of Mar. 2018)


View and export this data going back to 2007. Start your Free Trial

What is PositiveID Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Mar. 2018, PositiveID paid $0.00 Mil more to buy back shares than it received from issuing new shares. It received $0.80 Mil from issuing more debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $0.00 Mil on other financial activities. In all, PositiveID earned $0.80 Mil on financial activities for the three months ended in Mar. 2018.


PositiveID Cash Flow from Financing Historical Data

The historical data trend for PositiveID's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PositiveID Cash Flow from Financing Chart

PositiveID Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.39 2.55 5.18 3.53 1.81

PositiveID Quarterly Data
Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.58 0.07 0.31 0.84 0.80

PositiveID Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

PositiveID's Cash from Financing for the fiscal year that ended in Dec. 2017 is calculated as:

PositiveID's Cash from Financing for the quarter that ended in Mar. 2018 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PositiveID  (OTCPK:PSID) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

PositiveID's issuance of stock for the three months ended in Mar. 2018 was $0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

PositiveID's repurchase of stock for the three months ended in Mar. 2018 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

PositiveID's net issuance of debt for the three months ended in Mar. 2018 was $0.80 Mil. PositiveID received $0.80 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

PositiveID's net issuance of preferred for the three months ended in Mar. 2018 was $0.00 Mil. PositiveID paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

PositiveID's cash flow for dividends for the three months ended in Mar. 2018 was $0.00 Mil. PositiveID received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

PositiveID's other financing for the three months ended in Mar. 2018 was $0.00 Mil. PositiveID received $0.00 Mil on other financial activities.


PositiveID Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of PositiveID's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


PositiveID (PositiveID) Business Description

Traded in Other Exchanges
N/A
Address
1690 South Congress Avenue, Suite 201, Delray Beach, FL, USA, 33445
PositiveID Corp is a life science tools and diagnostics company. It specializes in the biological detection and molecular diagnostic systems for homeland defense and the global healthcare market. The business activity of the firm includes the development of microfluidic systems in order to detect biological threats and outbreaks, whether airborne, in a healthcare setting, or at the point of need through its subsidiary. Further, it is also involved in the development of FireflyDX family of products, automated pathogen detection system for rapid diagnostics, both for clinical and point-of-need applications. In addition, it also manufactures specialty technology vehicles focused primarily on mobile laboratory and communications applications. All the activities are carried out through the US.
Executives
Ned L Siegel director 600 WILSHIRE BOULEVARD, LOS ANGELES CA 90017
Michael E Krawitz director 1690 S CONGRESS AVE, STE 201, DELRAY BEACH FL 33445
Barry M Edelstein director 1100 GREEN VALLEY ROAD, BRYN MAWR PA 19010
Scott R Silverman other: Former 10% Owner
Marxe Austin W & Greenhouse David M 10 percent owner C/O SPECIAL SITUATIONS FUNDS, 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022
Weaver Constance K director 2900 ESPERANZA CROSSING, 2ND FLOOR, AUSTIN TX 78758
Tommy G Thompson director 7711 CARONDELET, ST. LOUIS MO 63105

PositiveID (PositiveID) Headlines

From GuruFocus

PositiveID's Chairman and CEO Addresses Stockholders

By Marketwired Marketwired 04-26-2018